Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.33 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9239478 | 0.79 | CRBN (0.37) | CRBNDDB1IKZF3 | |
| SCHEMBL1995236 | 0.79 | CRBN (0.36) | CRBNDDB1IKZF3 | |
| SCHEMBL15703044 | 0.75 | DDB1 (0.36) | CRBNDDB1 | |
| SCHEMBL33371399 | 0.69 | CRBN (0.33) | CRBNDDB1IKZF3 | |
| SCHEMBL68773 | 0.69 | CRBN (0.33) | CRBNDDB1IKZF3 | |
| SCHEMBL7099066 | 0.68 | CRBN (0.33) | CRBNDDB1IKZF3 | |
| SCHEMBL12473611 | 0.67 | CRBN (0.32) | CRBNDDB1 | |
| SCHEMBL9731788 | 0.62 | MAPT (0.34) | CRBNDDB1 | |
| SCHEMBL7985487 | 0.61 | CRBN (0.33) | CRBNDDB1IKZF3 | |
| SCHEMBL7098448 | 0.61 | CRBN (0.36) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936636-B2 | 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity | ALLERGAN, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| WO-2005000784-A2 | 5-[PHENYL, TETRAHYDRONAPHTHALENE-2-YL DIHYDRONAPHTHALEN-2-YL AND HETEROARYL- CYCLOPROPYL]-PENTADIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | ALLERGAN, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20050004213-A1 | 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity | ALLERGAN, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004213-A1 | 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity | PNLIP, TPO, MTTP | CRBN 2005/4885DDB1 1720/4885IKZF3 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.